0000000001157915

AUTHOR

Nicola Greenlaw

showing 3 related works from this author

Insufficient control of heart rate in stable coronary artery disease patients in Latvia

2014

Background and objective:\ud Heart rate (HR) ≥70 beats per minute (bpm) increases cardiovascular risk in coronary artery disease (CAD) patients. The objective of the analysis is to characterize HR as well as other clinical parameters in outpatients with stable CAD in Latvia.<p></p>\ud \ud Materials and methods:\ud CLARIFY is an ongoing international registry of outpatients with established CAD. Latvian data regarding 120 patients enrolled in CLARIFY and collected at baseline visit during 2009–2010 were analyzed.<p></p>\ud \ud Results:\ud The mean HR was 67.7 ± 9.5 and 66.9 ± 10.7 bpm when measured by pulse palpation and electrocardiography, respectively. HR &#8…

Malemedicine.medical_specialtyAdrenergic beta-AntagonistsHeart rateCoronary artery diseaseAngina PectorisNOCoronary artery diseaseElectrocardiographyInternal medicineHeart ratemedicineHumansRegistriesCarvedilolAgedMetoprololHeart FailureMedicine(all)lcsh:R5-920Framingham Risk ScoreCoronary artery disease; Heart rate; Outpatient; Medicine (all)business.industryMedicine (all)OutpatientMiddle Agedmedicine.diseaseLatviaNebivololTreatment OutcomeBisoprololHeart failureAutomotive EngineeringCardiologycardiovascular systemFemalelcsh:Medicine (General)businessHeart rate; Coronary artery disease; Outpatienthuman activitiesmedicine.drugcirculatory and respiratory physiologyMedicina
researchProduct

A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure

2015

Aims: Although active-controlled trials with renin–angiotensin inhibitors are ethically mandated in heart failure with reduced ejection fraction, clinicians and regulators often want to know how the experimental therapy would perform compared with placebo. The angiotensin receptor-neprilysin inhibitor LCZ696 was compared with enalapril in PARADIGM-HF. We made indirect comparisons of the effects of LCZ696 with putative placebos.\ud \ud Methods and results: We used the treatment-arm of the Studies Of Left Ventricular Dysfunction (SOLVD-T) as the reference trial for comparison of an ACE inhibitor to placebo and the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidit…

MaleTetrazolesAngiotensin-Converting Enzyme InhibitorsEnalaprilEnalapril/therapeutic useMedicineNatriuretic peptidesAngiotensin IIAminobutyratesHeart Failure/CardiomyopathyMiddle AgedAngiotensin Receptor Antagonists/therapeutic useHospitalizationAngiotensin-Converting Enzyme Inhibitors/therapeutic useDrug CombinationsTreatment OutcomeTetrazoles/therapeutic useCardiologyValsartanFemaleCardiology and Cardiovascular Medicinemedicine.drugBenzimidazoles/therapeutic usemedicine.medical_specialtyAngiotensin II Type 1 Receptor Blockers/therapeutic usemedicine.drug_classPlaceboAngiotensin Receptor AntagonistsInternal medicineHumansEnalaprilFASTTrack Clinical ResearchBeta blockerAgedHospitalization/statistics & numerical dataHeart Failurebusiness.industryBiphenyl Compoundsmedicine.diseaseHeart Failure/drug therapyPlacebo EffectAngiotensin IICandesartanEndocrinologyAminobutyrates/therapeutic useHeart failureACE inhibitorBenzimidazolesbusinessAngiotensin II Type 1 Receptor BlockersSacubitril ValsartanNatriuretic peptide
researchProduct

Management of coronary artery disease patients in Latvia compared with practice in Central-Eastern Europe and globally: Analysis of the CLARIFY regis…

2015

Background and objective: Management of outpatients with stable coronary artery disease (CAD) is important in secondary prevention. The objective was to describe differences in the characteristics of CAD patients in Latvia compared with other countries. Materials and methods: CLARIFY is an ongoing international, prospective, observational, longitudinal registry of outpatients with CAD. Data regarding treated outpatients with established CAD from the CLARIFY registry in Latvia (n = 120) were compared with those from the rest of Central-Eastern Europe (CEE) (n = 2888) and worldwide (n = 33,163). Results: Patients in Latvia had a larger waist circumference (101 [95–109] vs. 99 [91–106] in CEE,…

MaleMedicine (General)medicine.medical_specialtyWaistmedicine.medical_treatmentDiastoleCoronary artery disease; Latvia; Prevention; Risk factors; Medicine (all)Coronary artery diseaseBody Mass IndexNOCoronary artery diseaseR5-920Percutaneous Coronary InterventionGeneral & Internal MedicineInternal medicineSecondary PreventionmedicineHumansProspective StudiesRegistriesCoronary artery disease; Latvia; Risk factors; PreventionProspective cohort studyAgedMedicine(all)AspirinAspirinbusiness.industryPreventionMedicine (all)CLARIFY registry investigatorsPercutaneous coronary interventionMiddle Agedmedicine.diseaseLatviaBlood pressureRisk factorsEvidence-Based PracticeAutomotive EngineeringCardiologyFemaleWaist CircumferencebusinessBody mass indexmedicine.drugMedicina
researchProduct